Skip to main content
TipRanks
Go Ultimate75% OFF

MEDINET Co., Ltd. (2370) AI Stock Analysis

0 Followers
JP:2370

MEDINET Co., Ltd.

(TSE/TYO:2370)

Select Model
Rating:39Underperform
Price Target:JPY 16.00â–²(0.00% Upside)
Action:reiterated
Date:11/16/26

MEDINET Co., Ltd. receives a very low score primarily driven by severe operational cash burn and a firmly entrenched bearish technical downtrend. While the company maintains a zero-debt balance sheet that provides a minor safety net, staggering net losses and rapid equity erosion pose substantial long-term risks. Furthermore, negative earnings multiples highlight its highly speculative nature, with current technical indicators offering no signs of an impending momentum reversal.

Positive Factors
Revenue GrowthThe rise in revenue shows that MEDINET has continued expanding its commercial activity despite weak profitability. Sustained top-line progress can support operating leverage over time if the company converts growth into better margins and more efficient use of its healthcare data capabilities.
Negative Factors
Persistent UnprofitabilityLarge operating losses relative to revenue show that MEDINET has not yet established an economically sustainable operating model. Continued net losses limit internal funding capacity and indicate that additional revenue growth alone may not improve shareholder outcomes without substantial margin recovery.

MEDINET Co., Ltd. (2370) vs. iShares MSCI Japan ETF (EWJ)

-60%-40%-20%0%20%40%JP:2370-48.39%EWJ+14.66%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 4.55B
Dividend Yield
―
Average Volume (3M)
606.30K
Price to Earnings (P/E)
-3.1
Beta (1Y)
0.71
Revenue Growth
1.41%
EPS Growth
1.12%
Country
Japan
Employees
107
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

MEDINET Co., Ltd. Business Overview & Revenue Model

Company Description

Established in 1995 and headquartered in Tokyo, Japan, MEDINET Co., Ltd. functions as a contract development and manufacturing organization (CDMO) primarily focused on regenerative medicine and cell therapy solutions within Japan. The company furnish...

MEDINET Co., Ltd. Financial Statement Overview

Summary

Despite a pristine zero-debt balance sheet, the company faces severe structural cash burn, massive net losses with a -170% net profit margin, and rapidly declining stockholder equity, posing significant viability risks.

Income Statement

25Negative

Balance Sheet

55Neutral

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMSep 2026Sep 2025Sep 2024Sep 2023Sep 2022
Income Statement
Total Revenue724.63M821.73M810.29M768.50M661.54M633.67M
Gross Profit128.40M151.01M83.44M82.67M65.21M90.44M
EBITDA-1.29B-1.42B-1.26B-1.20B-1.36B-1.17B
Net Income-1.41B-1.40B-1.36B-1.28B-1.44B-1.25B
Balance Sheet
Total Assets6.35B3.58B4.25B5.70B5.63B6.08B
Cash, Cash Equivalents and Short-Term Investments5.03B2.42B3.17B4.65B4.40B4.50B
Total Debt91.32M00781.00K2.31M4.30M
Total Liabilities548.63M672.01M477.10M509.95M590.60M566.58M
Stockholders Equity5.80B2.91B3.78B5.19B5.04B5.51B
Cash Flow
Free Cash Flow0-1.35B-1.44B-1.25B-1.28B-1.14B
Operating Cash Flow0-1.33B-1.41B-1.19B-1.26B-1.13B
Investing Cash Flow0553.80M-565.17M-12.71M-2.16M-50.35M
Financing Cash Flow0532.79M-2.55M1.46B1.16B1.58B

MEDINET Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price16.00

Price Trends

50DMA22.08Negative
100DMA23.44Negative
200DMA26.33Negative

Market Momentum

MACD-1.66Positive
RSI26.57Positive
STOCH27.78Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2370, the sentiment is Negative. The current price of 16.00 is below the 20-day moving average (MA) of 19.25, below the 50-day MA of 22.08, and below the 200-day MA of 26.33, indicating a bearish trend. The MACD of -1.66 indicates Positive momentum. The RSI at 26.57 is Positive, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2370.

MEDINET Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:2370 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:2385JP:238567NeutralJPY 5.49B32.41―4.76%-33.44%3.65%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:2183JP:218350NeutralJPY 4.45B-1.23―4.06%-23.55%-205.65%
JP:2342JP:234244NeutralJPY 3.07B-165.15――8.53%97.93%
JP:2370JP:237039UnderperformJPY 4.55B-3.14――1.41%1.12%
JP:206AJP:206A37UnderperformJPY 3.11B-2.62――-23.40%-40.15%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%JP:2370JP:2183JP:2342JP:2385JP:206ADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:2370 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:2370MEDINET Co., Ltd.16.00-15.00-48.39%
JP:2183Linical Co., Ltd.197.00-94.98-32.53%
JP:2342Trans Genic Inc.182.00-44.00-19.47%
JP:2385Soiken Holdings Inc.210.00-5.82-2.69%
JP:206APRISM BioLab Co. LTD84.00-86.00-50.59%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 16, 2026